Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Author: search.filters.author.Mickovski, IvanaSubject: search.filters.subject.metabolic syndrome

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    METABOLIC SYNDROME (METS) AS ONE OF THE MAJOR COMORBIDITIES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    (Association of pulmologists from Republika Srpska, 2023-05)
    ;
    Baloski, Marjan
    ;
    Bushev, Jane
    ;
    ;
    Mickovski, Ivana
    Aim: We aimed to investigate the association between COPD and MetS, the relation to the severity of airflow limitation. Methods: This is a cross-sectional study including 220 patients with initially diagnosed COPD (IG), aged 40 to 75 years and 58 non-COPD subjects matched by age, smoking status, body mass index, as controls (CG). All study participants underwent anthropometric measurements, fasting blood sugar (FBS), lipid profile, pulmonary evaluation (dyspnea severity assessment, baseline and postbronchodilator spirometry, gas analyses, chest X-ray). Results: Results presented statistically significant difference in presence of MetS in COPD patients compared to controls (32.27% vs 10.34%; P=0.0009). According to the GOLD classification, the frequencies of MetS in COPD patients were categorized in stages I, II, III, IV (17.54%, 37.10%, 34.62%, 40.82%, respectively). The proportion of patients with increased glycemic values was: a) GOLD1 - 18 (31.58%); b) GOLD 2 - 32 (51.61%); c) GOLD3 - 29 (55.77%); and d) GOLD4 - 31 (63.27%). There was no significant difference between IG and CG patients regarding HDL level. According to arterial hypertension the highest proportion was observed in GOLD3 - 22 (42.31%) followed by GOLD4 - 20 (40.82%), and GOLD3 - 22 (35.48 %), smallest in GOLD1 - 17 (29.82%). Conclusion: We found higher prevalence of MetS in patients with COPD even in early COPD stages compared to non-COPD. Our findings suggest an urgent need to develop comprehensive strategies for prevention, screening and start of treatment in early stage.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Metabolic Syndrome (MetS) as a comorbidity of Chronic Obstructive Pulmonary Disease (COPD)
    (European Respiratory Society, 2021-09-05)
    ;
    ;
    Mickovski, Ivana
    ;
    Kamchevska, Nade Kochovska
    We aimed to investigate the association between COPD and MetS, the relation to the severity of airflow limitation and the level of serum C-reactive protein (CRP). Cross-sectional study including 120 patients with initially diagnosed COPD, aged 40-75 years and 60 non-COPD controls, matched by age, smoking status, body mass index. All study participants underwent anthropometric measurements, fasting blood sugar (FBS), lipid profile, CRP, pulmonary evaluation (dyspnea severity assessment, baseline and post-bronchodilator spirometry, gas analyses, chest X-ray). Results presented statistically significant difference in presence of MetS in COPD patients compared to controls (47.5% vs 20.0%, p=0.0004). According to the GOLD classification, the frequencies of MetS in COPD patients were categorized in stages I, II, III, IV (40.0%, 45.8%, 46.7%, 43.0% respectively), and according to combined assessment test in A, B, C, D (29.2%, 37.5%, 35.0%, 41.7% respectively). COPD patients with MetS presented significant association with CRP (p=0.001) and no association with pulmonary function. FBS was higher in COPD compared to controls (8.4±1.1mmol/L vs. 4.9±2.1mmol/L, p<0.0001), but HDL was lower in COPD than non-COPD (39.1±6.4mg/dl vs 49.6±3.9mg/dl, p<0.0001). Waist circumference and blood pressure (BP) were higher in COPD 95.8±3.4cm vs. control group 91.8±2.9cm, p<0.0001. Mean systolic BP was 138.3±12.2mmHg vs. 125.5±6.1mmHg, p<0.0001 in non-COPD. We found higher prevalence of MetS in patients with COPD even in early COPD stages compared to non-COPD group. Our findings suggest an urgent need to develop comprehensive strategies for prevention, screening and start of treatment in the early stage of the disease.